The joint venture, renamed Synovate, has received orders from the sport of badminton’s governing body and “Lapland UK”, a Christmas destination event near Ascot
Catenae Innovation PLC (LON:CTEA) said its 50/50 joint venture with BHA-Medical, now renamed Synovate Global, has received its first orders.
One order is from the sport of badminton’s governing body and the other is for use at “Lapland UK”, a Christmas destination event near Ascot in Surrey.
Neither order will generate significant revenues but the orders do provide a commercial endorsement for Synovate’s offering, Catenae said.
“We are delighted to officially launch Synovate and to be able to provide commercial organisations with a comprehensive offering that they can use to test and securely manage COVID-19 cases within their corporations. Importantly, Synovate ensures that results from both Antigen and Antibody test are fed into PHE [Public Health England], where, in turn, they are inputted into the NHS’s ‘Test and Trace’ platform. Our platform is able to accept tests results from a range of differing testing procedures and is also able to accept an individual’s vaccination information,” said Guy Meyer, the chief executive officer of Catenae in a statement.
Meyer added that the company is experiencing increased interest in Synovate’s services from organisations across a range of industries.
Read more:Catenae says orders are starting to trickle in at its joint venture with BHA-Medical